Table 2:

Cumulative Cardiac Based Study Outcomes

Cardiac Outcomes	On Protocol	Within 1 Year	Within 2 Years
Lowest LVEF, Median (IQR)	58 (52–64)	57 (51–63)	57 (51–63)
Final LVEF, Median (IQR)*	62 (58–67)	64 (58–68)	64 (58–68)
Final LVEF < 50%, N (%)	3 (9)	1 (3)	1 (3)
New LV Dysfunction ≥ 10% decrease to <50%, N (%)	2 (6)	3 (9)	3 (9)
Any LV Dysfunction (LVEF < 50%), N (%)	4 (12)	6 (18)	6 (18)
Asymptomatic LV Dysfunction, N (%)	2 (6)	3 (9)	2 (9)
Systolic HF, Grade II, N (%)	2 (6)	3 (9)	3 (9)
Systolic HF, Grade III or more, N (%)	0 (0)	0 (0)	0 (0)
Persistent LV Dysfunction, N (%)***	1 (3)	1 (3)	1 (3)
Symptomatic Diastolic HF (LVEF ≥ 50%)
Grade I or II, N (%)	0 (0)	1 (3)	2 (6)
Grade III or more HF, N (%)	0 (0)	3 (9)	4 (12)**
Myocarditis (On Checkpoint Inhibitor Therapy)	-	1 (3)	2 (6)
Cardiac Death****		1 (3)	1 (3)

All LVEF measurements per clinical echocardiogram. Persistent LV Dysfunction defined as two consecutive echocardiograms with LVEF <50%.

^*No difference between time points, p = NS.

^**Includes one patient with acute diastolic HF and segmental PE while on gemcitabine and docetaxel, one patient with admission for pneumonia complicated by acute HF, and two patients with checkpoint inhibitor associated myocarditis.

^***The only patient with persistent LV dysfunction had baseline LVEF < 50%.

^****Due to checkpoint inhibitor associated myocarditis.